Growth Hormone Studies
Ipamorelin 10MG
Selective GH secretagogue research peptide.
Specifications
- Form
- Lyophilized Powder
Description
Detailed research description coming soon.
Compound Guide
What is Ipamorelin?
Clean, Selective Growth-Hormone Signaling
Ipamorelin is a pentapeptide ghrelin-receptor agonist that prompts a pulsatile release of endogenous growth hormone. Its defining trait in the literature is selectivity: unlike earlier secretagogues, it shows minimal effect on cortisol, prolactin, or appetite, which is why it is often the reference compound in GH-axis studies.
Areas of Research Interest
Summarized from published research findings. Not medical guidance or prescribing information.
Metabolic Support
Studied for shifting substrate use toward stored fat, a common endpoint in body-composition research.
Lean Tissue Retention
GH pulses are associated with preservation of lean mass during caloric restriction models.
Slow-Wave Sleep
Endogenous GH release peaks in deep sleep; evening dosing is studied for sleep-architecture endpoints.
Skin & Collagen
Downstream IGF-1 signaling is examined for dermal elasticity and fine-line endpoints.
Bone & Joint
GH-axis research includes bone mineral density and connective-tissue integrity measures.
High Selectivity
Minimal cortisol and prolactin cross-activation compared with earlier-generation secretagogues.
Reconstitution
- 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL
- 10 mg vial + 4 mL bacteriostatic water = 2.5 mg/mL
- Both vials reconstitute to the same concentration, so unit counts stay identical
- 1 unit on a U-100 insulin syringe = 0.025 mg (25 mcg)
Suggested research protocol
- Route studied: subcutaneous, rotating sites across abdomen, outer thigh, and glute.
- Timing: evening, on an empty stomach 1–2 hours after the last meal, to align with the natural GH pulse.
- Cycle: 5 days on / 2 days off is the most common design; blocks of 3–6 months appear in longer studies.
- Use within 30 days of reconstitution; refrigerate.
Dosing Reference
| Week | Daily dose | U-100 units @ 2.5 mg/mL |
|---|---|---|
| Week 1 | 100 mcg | 4 units |
| Week 2 | 150 mcg | 6 units |
| Week 3 | 200 mcg | 8 units |
| Week 4+ | 250–300 mcg | 10–12 units |
Handling & Notes
- Mild transient redness at the administration site is the most commonly logged observation.
- A brief flush or warmth immediately after administration is reported and self-limiting.
- Widely characterized as one of the mildest compounds in the secretagogue class.
Stack Up
Compounds studied alongside Ipamorelin
This guide is provided for informational and research reference only. Ipamorelin is intended for laboratory research use exclusively and is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary consumption.